OLIGOFASTX is a multidisciplinary consortium composed of seven Spanish companies: Sylentis (PharmaMar Group; coordinating company), Nanovex Biotechnologies (Grupo Industrial Química del Nalón), Aptus Biotech, AptaTargets, Arthex Biotech, Nostrum Biodiscovery and 53Biologics.
Specialising in gene silencing with siRNA molecules
One of the pioneering European companies in its field. The design of their molecules/drugs is rational and is carried out using artificial intelligence techniques in computer systems. It develops and manufactures such molecules.
Rare diseases: Retinitis Pigmentosa, Leber Congenital Amaurosis (LCA) and retinal dystrophy associated with Alström Syndrome.Project role Corporate website
Company specialised in the development of nanoparticles and scaling for all kinds of applications, mainly in the pharmaceutical and cosmetic fields. This type of technology is essential to enable RNA molecules to reach their target cells and molecules.Project role Corporate website
Arthex, expert in anti-miRs design
Rare diseases: Myotonic dystrophy type 1 (DM1), Fuchs’ corneal dystrophy, and muscular atrophy due to cachexia in cancer.Project role Corporate website
Molecular modelling of oligonucleotides. Modelling and enzyme engineering.Project role Corporate website
Aptus biotech is the leading Spanish company dedicated to the development of aptamers. They are developed through a process called SELEX and are able to bind to all kinds of molecules, which makes them suitable for a wide range of therapeutic indications.Project role Corporate website
Apta Targets focuses on the development of aptamer-based clinical therapies.
Rare disease: Guillain-Barré syndrome.Project role Corporate website